Abivax SA: 5%+ holders

As of November 9, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Abivax SA. The largest reported stake is Chen Yu's, at 7%. 11 filings are on record since July 31, 2025 (Schedule 13G/A, August 14, 2026).

Sofinnova Crossover I SLP also filed stake reports on 1 other company ↓

Sell to companies like Abivax SA? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: TCG Crossover GP I, LLC · Sole voting: 0 · Shared voting: 4,924,377 · Sole dispositive: 0 · Shared dispositive: 4,924,377 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-13 · Reporting person: Invus Public Equities, L.P. · Sole voting: 4,790,187 · Shared voting: 0 · Sole dispositive: 4,790,187 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
• Filing 2026-07-06 · Reporting person: Sofinnova Crossover I SLP · Sole voting: 3,535,843 · Shared voting: 0 · Sole dispositive: 2,474,299 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-06
• Filed 2026-05-11 · Holder: Sofinnova Crossover I SLP · Percent: 6.7% · SCHEDULE 13D/A
• Filed 2026-02-13 · Holder: Invus Public Equities, L.P. · Percent: 5% · SCHEDULE 13G/A

Abivax SA has 11 Schedule 13D or 13G filings on record since 2025-07-31. 2 holders' latest filing reports 5% or more of ordinary shares, par value euro 0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Abivax SA and the warning signs.

See Abivax SA's free Snapshot Watch Abivax SA: email me the next time it files something

Free to see. No signup.

Keep reading

More on Abivax SA and the records around it.

Abivax SA elsewhere on the record

• Who owns it

Companies that share a holder

• Sofinnova Crossover I SLP also filed stake reports on 1 other company: Inventiva, S.A. (Feb 2026)
• TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Entrada Therapeutics, Inc. (Aug 2026), Vistagen Therapeutics, Inc. (Aug 2026), Savara Inc. (Feb 2026)
• Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), enGene Holdings Inc. (Aug 2026)

Want the whole picture on Abivax SA?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Abivax SA: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Abivax SA covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Abivax SA by CUSIP 00370M103 and gives its principal executive office as 7-11 boulevard Haussman, Paris (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

As of June 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on 79,800,669 Shares outstanding as of June 26, 2026, as reported in the Issuer's Form 424(b)(5) filed with the Securities and Exchange Commission on July 2, 2026.Invus Public Equities, L.P., SCHEDULE 13G/A, 2026-08-13

Purpose of Transaction (Item 4)

Sofinnova Crossover I SLP

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: SC sold the amounts of ADS and Ordinary Shares on the date and at the prices set forth below in open market transactions on NASDAQ and Euronext. All daily sales of the shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each weighted average price set forth in this Schedule 13D. June 30, 2026: -500,000 ADSs at a weighted average price of $132.7347 per share. July 1, 2026: -25,000 ADSs at a weighted average price of $134.2377 per share. July 2, 2026: -275,000 ADSs at a weighted average price of $140.9365 per share.* -35,469 Ordinary Shares at a weighted average price of $144.2752 per share.* July 3, 2026: -25,000 Ordinary Shares at a weighted average price of $156.2041 per share.* -39,531 Ordinary Shares at a weighted average price of $155.0654 per share.* July 6, 2026: -3,195 Ordinary Shares at a weighted average price of $155.0436 per share.* * Transaction completed in Euros. Price per share converted to USD at an exchange rate of $1.1448 as of July 3, 2026. All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-06; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Abivax SA

Who owns Abivax SA?

On this page, 2 holders' latest ownership filings report 5% or more of Abivax SA: Chen Yu (7%, Schedule 13G/A, filed 2026-08-14) and Invus Public Equities, L.P. (6%, Schedule 13G/A, filed 2026-08-13).

Who are the largest shareholders of Abivax SA?

By the share each holder's latest filing reports, the largest holders of Abivax SA on this page are Chen Yu (7%) and Invus Public Equities, L.P. (6%).

When did Chen Yu buy into Abivax SA?

The filings give report dates, not purchase dates. The earliest filing from Chen Yu on this page is the Schedule 13G/A, filed 2025-11-14, reporting 9.1%; its latest, Schedule 13G/A filed 2026-08-14, reports 7%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Abivax SA. With no account yet, you sign up free and land on the result.

• Get an alert when Abivax SA is mentioned again
• Find former Abivax SA employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes